Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Compare within a sector
MetricMRKMerck & Co.AZNAstraZeneca PLCNVSNovartis AG
Snapshot
Price$127.44$160.15$156.05
Market cap$319.99B$284.73B$261.56B
Valuation
P/E35.1x24.6x21.6x
Forward P/E50.2x18.4x19.8x
Growth
Revenue growth2.9%9.9%5.8%
EPS growth-48.3%33.7%9.3%
Profitability
Net margin13.6%17.2%24.1%
ROE17.9%22.3%31.7%
Balance sheet & cash
Debt / equity0.94x0.61x0.77x
Free cash flow yield2.9%3.1%4.2%
Dividend yield3.0%1.7%2.9%
Verdict
Investment ratingWeak· 40Favorable· 68Favorable· 67

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearMRKtoday $127AZNtoday $160NVStoday $156
2027$97.49 – $142.99+12% CAGR$160.60 – $235.55+47% CAGR$127.89 – $187.57+20% CAGR
2028$99.44 – $145.85+7% CAGR$214.74 – $314.95+40% CAGR$139.74 – $204.95+15% CAGR
2029$101.43 – $148.76+5% CAGR$287.13 – $421.13+38% CAGR$152.70 – $223.95+13% CAGR
2030$103.46 – $151.74+4% CAGR$383.92 – $563.09+37% CAGR$166.85 – $244.71+12% CAGR
2031$105.53 – $154.77+4% CAGR$513.34 – $752.90+36% CAGR$182.32 – $267.40+11% CAGR
5-yr CAGR-3.7% – 4.0%26.2% – 36.3%3.2% – 11.4%